Journal · Updated 2026-08-11
Gala GLP-1 Review 2026: The $149–$199 Range, and Why 'Confirm in Enrollment' Is the Price
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
Gala GLP-1 publishes a menu, not a number: per July 2026 captures, semaglutide at one seventy-nine standard "all doses," one ninety-nine on a three-month plan, one forty-nine microdosing; tirzepatide from one seventy-nine with a one forty-nine microdosing tier — with Gala's own materials directing buyers to confirm the exact rate in enrollment. Our tables rank the standard one seventy-nine (dose-flat, no membership, an honest mid-market figure tying Henry and bmiMD's monthly rates) and record the rest with labels. The two live questions: which figure applies to you (the enrollment confirmation is the price), and whether the microdosing discount survives the evidence audit — cheaper by dollars, cheaper by milligrams, unproven by trials.
The range, decoded
The one seventy-nine standard rate is Gala's real product: flat at every dose, both molecules, all-fifty-state provider claim, no membership line — structurally the Henry shape at the Henry price. The one ninety-nine three-month figure inverts the usual ladder (paying more on a plan is unusual; pin what it includes). And the one forty-nine microdosing tier is the market's clearest priced example of the pattern our microdosing analysis covers: a real discount for a sub-maintenance dose whose efficacy no trial supports — legitimate for tolerability or maintenance cases under prescriber direction, a false economy for anyone chasing full results at a discount. Pharmacy partner: not publicly named; standard extraction and verification apply.
Verdict
Ranked on the standard rate, Gala ties the one seventy-nine monthly tier — beaten by NexLife's promotional one sixty-nine on tirzepatide and by the one twenty-nine-to-one thirty-nine cluster on semaglutide, competitive with Henry and bmiMD's monthly plans, and ahead of everything from two hundred up. The fit: a buyer who wants dose-flat monthly simplicity and confirms two things in enrollment — the exact ongoing rate in writing, and the pharmacy name. If either comes back fuzzy, the same one seventy-nine exists at programs that print it on the label.
Questions people ask
How much does Gala GLP-1 actually cost?
Published range: semaglutide $179 standard 'all doses,' $199 on a three-month plan, $149 microdosing; tirzepatide from $179 with $149 microdosing (July 2026 captures). Gala directs buyers to confirm the exact rate in enrollment — so your enrollment confirmation, in writing, is your price. We rank the $179 standard figure.
Is Gala's $149 microdosing tier a good deal?
It's a real discount for a sub-maintenance dose — legitimate for prescriber-directed tolerability or maintenance cases, unsupported by any trial as a way to buy full results cheaper (the dose arms in SURMOUNT-1 say lower doses lose less). Ask the dose in mg, the escalation price, and why that dose for you.
Does Gala serve all 50 states?
It claims all-fifty-state provider coverage — broader than most compounded programs — with the standard intake-confirmation caveat, and its pharmacy partner isn't publicly named. Confirm state, rate, and pharmacy name in enrollment; all three take one message.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.